Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis

Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). However, patients often do not receive sacubitril/valsartan because of concerns about hypotension. We exami...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyoeun, Oh, Jaewon, Lee, Sanghyup, Ha, Jaehyung, Yoon, Minjae, Chun, Kyeong-hyeon, Lee, Chan Joo, Park, Sungha, Lee, Sang-Hak, Kang, Seok-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358003/
https://www.ncbi.nlm.nih.gov/pubmed/34381126
http://dx.doi.org/10.1038/s41598-021-95787-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358003/
https://www.ncbi.nlm.nih.gov/pubmed/34381126
http://dx.doi.org/10.1038/s41598-021-95787-w

Ejemplares similares